Cart
sales@molnova.com
PF-03814735
CAS No. 942487-16-3
PF-03814735( —— )
Catalog No. M17679 CAS No. 942487-16-3
PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 706 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF-03814735
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
-
DescriptionPF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAurora A| Aurora B|FLT1 |FAK| TrkA
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number942487-16-3
-
Formula Weight474.48
-
Molecular FormulaC23H25F3N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 47 mg/mL; 99.06 mM
-
SMILESCC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=C2C=CC(=C3)NC4=NC=C(C(=N4)NC5CCC5)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
16,17-Didehydroganod...
3,11,15,23-Tetraoxo-27ξ-lanosta-8,16-dien-26-oic acid, a lanostane-type triterpenoid, is isolated from Antrodia camphorate.
-
Phosphocreatine diso...
Phosphocreatine disodium salt hydrate ishigh-energy phosphate reservoir in vertebrate and some invertebrate muscle; provides phosphate for ADP-ATP conversion.
-
Cyanidin-3,5-O-diglu...
Cyanidin-3,5-O-diglucoside chloride has antioxidant activity. Cyanidin-3,5-O-diglucoside inhibits hyperbaric pressure-induced GLAST decrease and can be used in glaucoma studies.
